

Product datasheet for TL314798V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Angiopoietin 2 (ANGPT2) Human shRNA Lentiviral Particle (Locus ID 285)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Angiopoietin 2 (ANGPT2) Human shRNA Lentiviral Particle (Locus ID 285)

Locus ID: 285

Synonyms: AGPT2; ANG2; LMPHM10

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: ANGPT2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001118887, NM 001118888, NM 001147, NM 001147.1, NM 001147.2, NM 001118888.1,

NM 001118887.1, BC126202, BC022490, BC126200, BC143902, NM 001118887.2,

NM 001118888.2, NM 001147.3

UniProt ID: <u>015123</u>

Summary: This gene belongs to the angiopoietin family of growth factors. The protein encoded by this

gene is an antagonist of angiopoietin 1, and both angiopoietin 1 and angiopoietin 2 are ligands for the endothelial TEK receptor tyrosine kinase. Angiopoietin 2 is upregulated in multiple inflammatory diseases and is implicated in the direct control of inflammation-related signaling pathways. The encoded protein affects angiogenesis during embryogenesis and tumorigenesis, disrupts the vascular remodeling ability of angiopoietin 1, and may induce endothelial cell apoptosis. This gene serves a prognostic biomarker for acute respiratory

distress syndrome. [provided by RefSeq, Aug 2020]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).